196 related articles for article (PubMed ID: 8976184)
1. Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients.
Silvestris F; Nagata S; Cafforio P; Silvestris N; Dammacco F
J Exp Med; 1996 Dec; 184(6):2287-300. PubMed ID: 8976184
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of an eight amino acid domain shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and antigenic analysis.
Silvestris F; Cocco T; Cafforio P; Calvani N; Dammacco F
Mol Med; 2000 Jun; 6(6):494-508. PubMed ID: 10972086
[TBL] [Abstract][Full Text] [Related]
3. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
4. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis.
Silvestris F; Cafforio P; Frassanito MA; Tucci M; Romito A; Nagata S; Dammacco F
AIDS; 1996 Feb; 10(2):131-41. PubMed ID: 8838700
[TBL] [Abstract][Full Text] [Related]
6. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
7. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
[TBL] [Abstract][Full Text] [Related]
8. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
[TBL] [Abstract][Full Text] [Related]
9. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
10. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
[TBL] [Abstract][Full Text] [Related]
11. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
12. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
[TBL] [Abstract][Full Text] [Related]
13. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
14. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
[TBL] [Abstract][Full Text] [Related]
15. Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.
Chan KW; Pan R; Costa M; Gorny MK; Wang S; Lu S; Kong XP
J Virol; 2018 Sep; 92(18):. PubMed ID: 29997214
[TBL] [Abstract][Full Text] [Related]
16. Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.
Broliden PA; Mäkitalo B; Akerblom L; Rosen J; Broliden K; Utter G; Jondal M; Norrby E; Wahren B
Immunology; 1991 Aug; 73(4):371-6. PubMed ID: 1916888
[TBL] [Abstract][Full Text] [Related]
17. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells.
Ota A; Bautista AN; Yadav ML; Ueda S
Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013
[TBL] [Abstract][Full Text] [Related]
18. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
19. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
Trujillo JR; Rogers RA; Brain JD
Virology; 1998 Jun; 246(1):53-62. PubMed ID: 9656993
[TBL] [Abstract][Full Text] [Related]
20. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
